Antisoma Plunges After Late-Stage Cancer Trial Halted
This article is for subscribers only.
Antisoma Plc fell the most in more than 10 years in London trading after the U.K. company said a late-stage trial of the experimental lung cancer treatment ASA404 will be stopped because the medicine doesn’t work.
Antisoma plunged 24 pence, or 75 percent, to close at 8 pence. It was the biggest drop since December 1999.